Kurve Therapeutics Announces Development of New Intellectual Property to Target Drug Delivery in the Brain
Today, Kurve Therapeutics announced it has filed for new intellectual property on its nose to brain technology platform. Kurve’s technology uses the neuronal pathway rather than the circulatory system, which means the drug is delivered to the extracellular space in the brain. This means there is the opportunity to move the drug once it reaches the brain. The new IP will incorporate this ability allowing for treatments throughout the brain rather than just the frontal lobe. In contrast, the circulatory system traps the drug in the blood vessels blocking the opportunity to move the drug to a desired target.
Marc Giroux, CEO of Kurve Therapeutics, said, “We have been successfully delivering medications to the brain intranasally for more than a decade, and we learned a lot from the variety of formulations and conditions in which we have been involved. So, it gives me great pleasure to announce that we are developing technology that will allow us to target where the drug goes once it has been delivered to the brain. R&D is working diligently to get test results by the end of the year.”
Mr. Giroux further explained that while Kurve Therapeutics has proven successful at delivering medication to the frontal lobe with access to the hippocampus and, to some extent, to the brain stem, there was simply no way to focus delivery of medications to the sides, posterior, or center mass of the brain. He went on, “What happens if the condition was not frontally located, or a targeted tumor was toward the back of the brain? It is clear that we need the means to target these areas; we have filed a patent application covering a credible, promising solution. I believe we have figured it out.”
While performing this work, Mr. Giroux combined the chemistry, biology, and physics learned over the years into a solution for this critical issue. Since Kurve’s technology platform circumvents rather than uses the circulatory system (particularly with larger molecules), drugs are not confined to the bloodstream. Instead, clinicians will be able to relocate them within the cerebral spinal fluid (CSF) space surrounding the brain. This capability will allow for a greater concentration of drugs in the central nervous system, decreasing systemic exposure and broadening the therapeutic window. This outcome, in turn, expands the range of agents that could be viable CNS drugs. In addition, in a head-to-head measure in a clinical study in Southern California, Kurve’s technology delivered 3,000% more medication into the brain than an infusion. This result gives the formulators tremendous dose flexibility in the toxicity levels of the drug.
Delivering a drug to the brain and then relocating it to a target area should put Kurve Therapeutics at the vanguard of CNS and glioblastoma delivery and treatment. Kurve looks forward to working with its pharmaceutical partners to progress this new technology. Details on how the technology platform functions are available through Kurve Therapeutics under an NDA.
- Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer Read more
- BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Read more
- Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read more
- Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Read more
- Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President Read more